JP2004520324A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004520324A5 JP2004520324A5 JP2002552903A JP2002552903A JP2004520324A5 JP 2004520324 A5 JP2004520324 A5 JP 2004520324A5 JP 2002552903 A JP2002552903 A JP 2002552903A JP 2002552903 A JP2002552903 A JP 2002552903A JP 2004520324 A5 JP2004520324 A5 JP 2004520324A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- carbamoyl
- compound
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 69
- 229910052757 nitrogen Inorganic materials 0.000 claims 34
- 150000001875 compounds Chemical class 0.000 claims 32
- -1 cyano, hydroxy Chemical group 0.000 claims 26
- 125000000623 heterocyclic group Chemical group 0.000 claims 21
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 18
- 239000000651 prodrug Substances 0.000 claims 17
- 229940002612 prodrug Drugs 0.000 claims 17
- 239000012453 solvate Substances 0.000 claims 17
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 14
- 229910052799 carbon Inorganic materials 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 125000004452 carbocyclyl group Chemical group 0.000 claims 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 10
- 125000001475 halogen functional group Chemical group 0.000 claims 9
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 8
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 8
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 5
- 125000005236 alkanoylamino group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 208000030814 Eating disease Diseases 0.000 claims 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 3
- 125000004423 acyloxy group Chemical group 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 3
- 235000014632 disordered eating Nutrition 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 2
- 102000028582 Neuropeptide Y5 receptor Human genes 0.000 claims 2
- 108010046593 Neuropeptide Y5 receptor Proteins 0.000 claims 2
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 claims 1
- BFIJOYZWCZCWDI-UHFFFAOYSA-N 1-n-(2,4-dimethyl-9-propan-2-ylcarbazol-3-yl)-3-n-methylpiperidine-1,3-dicarboxamide Chemical compound C1C(C(=O)NC)CCCN1C(=O)NC1=C(C)C=C(N(C(C)C)C=2C3=CC=CC=2)C3=C1C BFIJOYZWCZCWDI-UHFFFAOYSA-N 0.000 claims 1
- OWFBVZBGOIYECX-UHFFFAOYSA-N 1-n-(2,4-dimethyl-9-propan-2-ylcarbazol-3-yl)piperidine-1,3-dicarboxamide Chemical compound CC=1C=C2N(C(C)C)C3=CC=CC=C3C2=C(C)C=1NC(=O)N1CCCC(C(N)=O)C1 OWFBVZBGOIYECX-UHFFFAOYSA-N 0.000 claims 1
- LVVQMWROURBWIV-UHFFFAOYSA-N 1-n-(4-methyl-9-propan-2-ylcarbazol-3-yl)piperidine-1,3-dicarboxamide Chemical compound C=1C=C2N(C(C)C)C3=CC=CC=C3C2=C(C)C=1NC(=O)N1CCCC(C(N)=O)C1 LVVQMWROURBWIV-UHFFFAOYSA-N 0.000 claims 1
- WZBUYBRFHLEIOK-UHFFFAOYSA-N 2-(1,1-dioxothiolan-3-yl)-n-(4-methyl-9-propan-2-ylcarbazol-3-yl)acetamide Chemical compound C=1C=C2N(C(C)C)C3=CC=CC=C3C2=C(C)C=1NC(=O)CC1CCS(=O)(=O)C1 WZBUYBRFHLEIOK-UHFFFAOYSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- QIUDGKAHVVYPHK-UHFFFAOYSA-N 3-n-(2,4-dimethyl-9-propan-2-ylcarbazol-3-yl)-1-n,1-n-dimethylpyrrolidine-1,3-dicarboxamide Chemical compound CC=1C=C2N(C(C)C)C3=CC=CC=C3C2=C(C)C=1NC(=O)C1CCN(C(=O)N(C)C)C1 QIUDGKAHVVYPHK-UHFFFAOYSA-N 0.000 claims 1
- WCIANFVRUMSDGK-UHFFFAOYSA-N 4-n-(2,4-dimethyl-9-propan-2-ylcarbazol-3-yl)-1-n,1-n-dimethylpiperidine-1,4-dicarboxamide Chemical compound CC=1C=C2N(C(C)C)C3=CC=CC=C3C2=C(C)C=1NC(=O)C1CCN(C(=O)N(C)C)CC1 WCIANFVRUMSDGK-UHFFFAOYSA-N 0.000 claims 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000004468 heterocyclylthio group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 239000012948 isocyanate Substances 0.000 claims 1
- 150000002513 isocyanates Chemical class 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- ZNFMHLDBJPAFEQ-UHFFFAOYSA-N n-(4-methyl-9-propan-2-ylcarbazol-3-yl)morpholine-4-carboxamide Chemical compound C=1C=C2N(C(C)C)C3=CC=CC=C3C2=C(C)C=1NC(=O)N1CCOCC1 ZNFMHLDBJPAFEQ-UHFFFAOYSA-N 0.000 claims 1
- VRBFOCCJIARKLA-UHFFFAOYSA-N n-(6-fluoro-4-methyl-9-propan-2-ylcarbazol-3-yl)-4-hydroxypiperidine-1-carboxamide Chemical compound C=1C=C2N(C(C)C)C3=CC=C(F)C=C3C2=C(C)C=1NC(=O)N1CCC(O)CC1 VRBFOCCJIARKLA-UHFFFAOYSA-N 0.000 claims 1
- CVCCDFPEKAUSBB-UHFFFAOYSA-N n-(6-fluoro-4-methyl-9-propan-2-ylcarbazol-3-yl)morpholine-4-carboxamide Chemical compound C=1C=C2N(C(C)C)C3=CC=C(F)C=C3C2=C(C)C=1NC(=O)N1CCOCC1 CVCCDFPEKAUSBB-UHFFFAOYSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0031382.5A GB0031382D0 (en) | 1998-06-10 | 2000-12-22 | Chemical compounds |
| GBGB0121919.5A GB0121919D0 (en) | 2001-09-11 | 2001-09-11 | Chemical compounds |
| PCT/GB2001/005577 WO2002051806A1 (en) | 2000-12-22 | 2001-12-17 | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004520324A JP2004520324A (ja) | 2004-07-08 |
| JP2004520324A5 true JP2004520324A5 (https=) | 2005-12-22 |
Family
ID=26245475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002552903A Pending JP2004520324A (ja) | 2000-12-22 | 2001-12-17 | カルバゾール誘導体およびニューロペプチドｙ５受容体リガンドとしてのそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20040067999A1 (https=) |
| EP (1) | EP1358157A1 (https=) |
| JP (1) | JP2004520324A (https=) |
| CN (1) | CN1531527A (https=) |
| BR (1) | BR0116388A (https=) |
| CA (1) | CA2432008A1 (https=) |
| IL (1) | IL156487A0 (https=) |
| MX (1) | MXPA03005648A (https=) |
| NO (1) | NO20032842L (https=) |
| NZ (1) | NZ526623A (https=) |
| WO (1) | WO2002051806A1 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0010757D0 (en) | 2000-05-05 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
| GB0121941D0 (en) | 2001-09-11 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| US6949564B2 (en) | 2002-12-18 | 2005-09-27 | Pfizer Inc. | NPY-5 antagonists |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2005090340A1 (ja) * | 2004-03-22 | 2005-09-29 | Banyu Pharmaceutical Co., Ltd. | ピペリジン－１－カルボキサミド誘導体 |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| ITMI20051523A1 (it) | 2005-08-03 | 2007-02-04 | Acraf | Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo |
| EP2520567A3 (en) | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| US7601856B2 (en) | 2006-07-27 | 2009-10-13 | Wyeth | Benzofurans as potassium ion channel modulators |
| EP2081905B1 (en) * | 2006-07-28 | 2012-09-12 | Boehringer Ingelheim International GmbH | Sulfonyl compounds which modulate the cb2 receptor |
| CA2664310A1 (en) | 2006-09-25 | 2008-04-03 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| WO2008064054A2 (en) * | 2006-11-21 | 2008-05-29 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| EP2527360B1 (en) | 2007-06-04 | 2015-10-28 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| JP5492092B2 (ja) * | 2007-11-07 | 2014-05-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節する化合物 |
| EP2119705A1 (en) | 2008-05-14 | 2009-11-18 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. | 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP2326629B1 (en) * | 2008-07-10 | 2013-10-02 | Boehringer Ingelheim International GmbH | Sulfone compounds which modulate the cb2 receptor |
| EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| WO2010036630A2 (en) | 2008-09-25 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the cb2 receptor |
| WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| AR074052A1 (es) | 2008-10-22 | 2010-12-22 | Array Biopharma Inc | Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa |
| JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
| US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| JP5756800B2 (ja) | 2009-06-16 | 2015-07-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体 |
| JP2013505295A (ja) * | 2009-09-22 | 2013-02-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を選択的に調節する化合物 |
| US9315454B2 (en) | 2010-01-15 | 2016-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| EP2542539B1 (en) | 2010-03-05 | 2014-02-26 | Boehringer Ingelheim International GmbH | Tetrazole compounds which selectively modulate the cb2 receptor |
| JP5746764B2 (ja) | 2010-07-22 | 2015-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節する化合物 |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| BR112013021236B1 (pt) | 2011-02-25 | 2021-05-25 | Merck Sharp & Dohme Corp | composto derivado de benzimidazol, e, composição |
| US9527875B2 (en) | 2012-08-02 | 2016-12-27 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| SI3004138T1 (sl) | 2013-06-05 | 2024-07-31 | Bausch Health Ireland Limited | Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| ES2987474T3 (es) | 2016-04-04 | 2024-11-15 | Loxo Oncology Inc | Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida |
| ES2836222T3 (es) * | 2016-05-18 | 2021-06-24 | Loxo Oncology Inc | Preparación de (S)-N-(5-((R)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| CA3138280A1 (en) * | 2019-05-01 | 2020-11-05 | Transfusion Health, Llc | Compositions and methods of making expanded hematopoietic stem cells using derivatives of carbazole |
| EP4125874A4 (en) * | 2020-03-25 | 2024-05-01 | SRI International | LIPOXYGENASE INHIBITORS |
| WO2023220558A1 (en) * | 2022-05-09 | 2023-11-16 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Combination of curaxins and immune checkpoint inhibitors for treating cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4111850A (en) * | 1977-02-16 | 1978-09-05 | Amp Incorporated | Organic photoconductors and methods |
| FR2546163B1 (fr) * | 1983-05-16 | 1987-10-09 | Centre Nat Rech Scient | Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application |
| US5234942A (en) * | 1984-10-19 | 1993-08-10 | Ici Americas Inc. | Heterocyclic amides and leucotriene antagonistic use thereof |
| GB8524157D0 (en) * | 1984-10-19 | 1985-11-06 | Ici America Inc | Heterocyclic amides |
| US5254135A (en) * | 1989-10-20 | 1993-10-19 | L'oreal | Methods for dyeing keratinous fibres with aminoindoles, compositions and devices for use |
| CA2242351C (en) * | 1996-01-10 | 2003-03-11 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel tricyclic compounds and drug compositions containing the same |
| WO2000063171A1 (en) * | 1999-04-20 | 2000-10-26 | Meiji Seika Kaisha, Ltd. | Tricyclic compounds |
| AU6000900A (en) * | 1999-07-23 | 2001-02-13 | Astrazeneca Uk Limited | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
-
2001
- 2001-12-17 IL IL15648701A patent/IL156487A0/xx unknown
- 2001-12-17 BR BR0116388-4A patent/BR0116388A/pt not_active IP Right Cessation
- 2001-12-17 JP JP2002552903A patent/JP2004520324A/ja active Pending
- 2001-12-17 CA CA002432008A patent/CA2432008A1/en not_active Abandoned
- 2001-12-17 CN CNA018228259A patent/CN1531527A/zh active Pending
- 2001-12-17 EP EP01272068A patent/EP1358157A1/en not_active Withdrawn
- 2001-12-17 MX MXPA03005648A patent/MXPA03005648A/es unknown
- 2001-12-17 US US10/450,928 patent/US20040067999A1/en not_active Abandoned
- 2001-12-17 WO PCT/GB2001/005577 patent/WO2002051806A1/en not_active Ceased
- 2001-12-17 NZ NZ526623A patent/NZ526623A/en unknown
-
2003
- 2003-06-20 NO NO20032842A patent/NO20032842L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004520324A5 (https=) | ||
| JP2006524222A5 (https=) | ||
| JP2014506599A5 (https=) | ||
| JP2006509749A5 (https=) | ||
| CA2545527A1 (en) | Pyrazole derivatives as inhibitors of receptor tyrosyne kinases | |
| JP2002539187A (ja) | アミド誘導体 | |
| JP2005526723A5 (https=) | ||
| JP2007520440A5 (https=) | ||
| WO2000047558A1 (en) | Amide compounds and medicinal use thereof | |
| JP2012507566A5 (https=) | ||
| JP2012505234A5 (https=) | ||
| JP2004518723A5 (https=) | ||
| JP2009523760A5 (https=) | ||
| JP2010538001A5 (https=) | ||
| JP2013518129A5 (https=) | ||
| JP2012510989A5 (https=) | ||
| JP2006514626A5 (https=) | ||
| JP2004525150A5 (https=) | ||
| JP2010090138A5 (https=) | ||
| JP2010510242A5 (https=) | ||
| JP2002030084A5 (https=) | ||
| WO2002022556A1 (en) | Novel amide derivatives and medicinal use thereof ugs | |
| JP2007522142A5 (https=) | ||
| JP2008505107A5 (https=) | ||
| JP4908233B2 (ja) | キナーゼ阻害剤として有用な１Ｈ−チエノ［２，３−ｃ］ピラゾール誘導体 |